Reported Earnings • Aug 13
First half 2026 earnings released: EPS: CHF0.99 (vs CHF1.41 in 1H 2025) First half 2026 results: EPS: CHF0.99 (down from CHF1.41 in 1H 2025). Revenue: CHF427.5m (down 2.7% from 1H 2025). Net income: CHF12.3m (down 32% from 1H 2025). Profit margin: 2.9% (down from 4.1% in 1H 2025). Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance. Tillkännagivande • Aug 11
Tecan Group AG to Report Q3, 2026 Results on Nov 05, 2026 Tecan Group AG announced that they will report Q3, 2026 results on Nov 05, 2026 Buy Or Sell Opportunity • Jun 03
Now 20% undervalued Over the last 90 days, the stock has risen 21% to CHF158. The fair value is estimated to be CHF198, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 9.5% over the last 3 years. Meanwhile, the company became loss making. Tillkännagivande • May 13
Tecan Group AG Reaffirms Earnings Guidance for the Year 2026 Tecan Group AG reaffirmed earnings guidance for the year 2026. The company reaffirms its 2026 guidance, as most recently communicated on March 16, 2026, with sales growth in the low single-digit percentage range in local currencies. Tillkännagivande • Apr 16
Tecan Group Ag Announces Executive Changes Tecan Group AG in its AGM meeting held on April 15, 2026, announced that shareholders elected three new members of the Board of Directors: Nina Beikert, Gitte Pugholm Aabo and Guillaume Daniellot. Matthias Gillner, who has been a member of the Board of Directors since 2023 and its Vice-Chairman, was elected as the new Chairman. He will step down as Chair of the Audit Committee but will remain a member, alongside Guillaume Daniellot and Gitte Pugholm Aabo. With the addition of the newly elected members, the Board of Directors will once again comprise seven members, ensuring an optimal balance of expertise, skills, and experience for the future. Lukas Braunschweiler, Chairman and a member of the Board since 2018, did not stand for re-election. Tillkännagivande • Mar 30
The Tecan Group Announces the Appointment of Camila Japur as Chief Financial Officer, Effective on June 1, 2026 The Tecan Group announced the appointment of Camila Japur as Chief Financial Officer, who will join the company on June 1, 2026. Camila currently serves as Group CFO of u-blox, where she has successfully led transformation initiatives, driving cost efficiency, strengthening financial processes, and enhancing capital market engagement. Prior to this, Camila spent 24 years at Ericsson, including seven years as CFO for the Enterprise Segment. Camila has an MBA from Fundação Getulio Vargas in São Paulo and a Bachelor's Degree in Economics from Universidade Mackenzie in São Paulo. Tillkännagivande • Mar 25
Tecan Group AG Announces Member of the Board of Directors Oliver Fetzer Will Not Stand for Re-Election Tecan Group AG announced that Oliver Fetzer, a member of the Board since 2011, has decided not to stand for re-election at the AGM to be held on April 15, 2026. Tillkännagivande • Dec 19
Tecan Group AG to Report First Half, 2026 Results on Aug 11, 2026 Tecan Group AG announced that they will report first half, 2026 results on Aug 11, 2026 Tillkännagivande • Dec 05
Tecan Group AG, Annual General Meeting, Apr 15, 2026 Tecan Group AG, Annual General Meeting, Apr 15, 2026. Tillkännagivande • Dec 04
ecan Group AG Announces Chairman of the Board of Directors Lukas Braunschweiler Will Not Stand for Re-Election Tecan Group AG announced that Lukas Braunschweiler, Chairman of the Board of Directors and a member of the Board since 2018, will not stand for re-election. Tillkännagivande • Dec 02
Tecan Group AG (SWX:TECN) acquired Wako Automation. Tecan Group AG (SWX:TECN) acquired Wako Automation on December 1, 2025.
Tecan Group AG (SWX:TECN) completed the acquisition of Wako Automation on December 1, 2025. Tillkännagivande • Oct 13
Tecan Reaffirms Earnings Guidance for the Year 2025 Tecan reaffirmed earnings guidance for the year 2025. For the year, Tecan confirmed its full-year sales outlook, expecting sales in local currencies to be within the previously communicated range – from a low single-digit percentage decline to low single-digit percentage growth, with current trends indicating that full-year performance will be in the lower half of the range. Tecan also reiterates its mid-term outlook, anticipating a return to average organic growth rates in the mid- to high-single-digit percentage range in local currencies under normal market conditions, while continuously improving profitability. However, end markets are expected to recover gradually, so a full normalization is not anticipated in 2026. Guidance for 2026 will be provided, as usual, with the full-year 2025 results in March 2026. Tillkännagivande • Oct 10
Tecan Group AG to Report Fiscal Year 2025 Results on Mar 16, 2026 Tecan Group AG announced that they will report fiscal year 2025 results on Mar 16, 2026 Tillkännagivande • Sep 13
Tecan Group AG Announces Change of Leadership in the Partnering Business Division The Tecan Group announced a change of leadership in its Partnering Business division. Ralf Griebel, who has served as Head of the Partnering Business division and as a member of the Management Board since April 2020, will be leaving the Company to pursue other opportunities. Monica Manotas will assume interim leadership of the Partnering Business division, taking this as an opportunity to work more closely with the business. Tillkännagivande • Apr 04
Tecan Group AG (SWX:TECN) signed an agreement to acquire Certain assets relating to key ELISA immunoassay products from Cisbio Bioassays SAS. Tecan Group AG (SWX:TECN) signed an agreement to acquire Certain assets relating to key ELISA immunoassay products from Cisbio Bioassays SAS on April 3, 2025. The asset purchase includes the manufacturing process of four ELISA kits – two in vitro diagnostic (IVD) products for specialty diagnostics and disease monitoring, and two research-use-only (RUO) kits. To ensure uninterrupted availability of these four ELISA kits until completion of the asset transfer, IBL International GmbH, a Tecan company, has signed a Master Distributorship Agreement with Cisbio Bioassays to resell the kits. Tillkännagivande • Mar 24
Tecan Group AG(SWX:TECN) dropped from FTSE All-World Index (USD) Tecan Group AG(SWX:TECN) dropped from FTSE All-World Index (USD) Tillkännagivande • Mar 19
Tecan Group AG, Annual General Meeting, Apr 10, 2025 Tecan Group AG, Annual General Meeting, Apr 10, 2025, at 15:00 W. Europe Standard Time. Tillkännagivande • Mar 06
Tecan Group AG to Report Q4, 2024 Results on Jun 12, 2025 Tecan Group AG announced that they will report Q4, 2024 results at 6:00 AM, Central European Standard Time on Jun 12, 2025 Tillkännagivande • Jan 28
Tecan Introduces Veya: Bringing Digital, Scalable Automation to Labs Worldwide Tecan announced the unveiling of Veya™, a transformative liquid handling platform designed to bring efficiency, precision and compliance to laboratories of all sizes. The platform, showcased at the Society for Laboratory Automation and Screening (SLAS) international conference, San Diego, underscores Tecan’s continued commitment to innovation and the democratization of lab automation. Veya overcomes key barriers in lab automation by offering an accessible and versatile platform that streamlines complex workflows and enables data-driven decision-making, while reducing downtime and enhancing productivity. Veya combines AI-enhanced automation, prebuilt workflows and an intuitive analytics interface, OneView™, to simplify complex tasks, including multiomics workflows. Its seamless integration with existing systems enables laboratories to boost productivity and meet important regulatory standards, including Europe’s CE-IVD and IVDR requirements. Key features of Veya: Simplified automation: Predeveloped workflows, intelligent analytics and a modular design boost productivity while reducing errors. Users report improvements of more than 60% in instrument utilization. High precision: Equipped with patented Air Restriction Pipetting (ARP), Veya handles volumes from 1 µl to 5 ml with precision. Real-time data: Improves decision-making and process optimization with live monitoring and actionable insights via a user-friendly interface. Continuous support: Features include 24-hour remote diagnostics, remote-guided troubleshooting and tailored service packages to minimize unplanned interruptions. Regulatory compliance: Veya is ideal for labs in regulated environments, ensuring compliance with key industry standards and regulatory requirements. Veya reflects Tecan’s commitment to democratize automation for laboratories of all sizes, including those constrained by budget or resources. By providing scalable, versatile and intuitive solutions for the ever-evolving needs of scientific research and diagnostics, Tecan continues to scale healthcare innovation globally. Tillkännagivande • Dec 17
Tecan Group AG to Report First Half, 2025 Results on Aug 12, 2025 Tecan Group AG announced that they will report first half, 2025 results on Aug 12, 2025 Tillkännagivande • Jun 25
Tecan Appoints Mukta Acharya as Head of the Life Sciences Business Division, Effective from August 1, 2024 Tecan Group AG announced that Mukta Acharya, currently serving as President, Tecan Americas, has been appointed the new Head of the Life Sciences Business division and a member of the Management Board of the Tecan Group. She is expected to assume her new position on August 1, 2024. Dr. Klaus Lun, Head of the Life Sciences Business since 2017 and a member of the Management Board since 2013, has decided to leave the company to pursue other career opportunities. Mukta Acharya joined Tecan in July 2022 as President, Tecan Americas, where she was responsible for the successful financial and market performance of the Life Sciences Business division in the company’s sales region. Mukta Acharya joined Tecan from Thermo Fisher Scientific, where she most recently served as Vice President and General Manager of the Single-use Flexible Solutions business. In this role, she drove the strategic growth of the global business, which spanned multiple manufacturing sites and thousands of employees worldwide. She also oversaw product management, marketing, engineering, and business development across the organization's various business units. From 2010 to 2018, Mukta Acharya held leadership positions at CVS Health, most recently as Director, Enterprise Product Innovation & Management. Prior to that, she worked in management consulting. She has a bachelor’s degree in Mechanical Engineering from India and a master’s degree in Engineering Management from Dartmouth College in the United States. Under Klaus Lun’s leadership, the Life Sciences Business division achieved significant growth and successfully navigated the challenges of the Covid-19 pandemic. Tecan’s Board of Directors and CEO would like to express their sincere gratitude to Klaus Lun for his strong engagement and important service of developing Tecan's Life Sciences Business and wish him all the best for the future. Tillkännagivande • Apr 20
Tecan Group Approves Dividend, Payable on April 24, 2024 Tecan Group announced that at its AGM held on April 18, 2024, shareholders approved to an increase in the dividend from CHF 2.90 to CHF 3.00 per registered share. Half of the dividend, i.e., CHF 1.50, will be paid out from the available capital contribution reserve and is therefore not subject to withholding tax. The payout will take place on April 24, 2024. Tillkännagivande • Apr 19
Tecan Group Elects Monica Manotas as Additional Independent Member of the Board of Directors Tecan Group announced that at its AGM held on April 18, 2024, the shareholders elected Monica Manotas as an additional independent member of the Tecan Board of Directors. With her many years of international experience in the life science industry and her proven expertise in finance, the industrial engineer with Colombian and US citizenship will strengthen the Board in a variety of ways. Upcoming Dividend • Apr 15
Upcoming dividend of CHF3.00 per share Eligible shareholders must have bought the stock before 22 April 2024. Payment date: 24 April 2024. Payout ratio is a comfortable 29% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of British dividend payers (6.1%). Higher than average of industry peers (0.6%). Declared Dividend • Mar 15
Dividend increased to CHF3.00 Dividend of CHF3.00 is 3.4% higher than last year. Ex-date: 22nd April 2024 Payment date: 24th April 2024 Dividend yield will be 0.8%, which is higher than the industry average of 0.5%. Payout Ratios Payout ratio: 29%. Cash payout ratio: 31%. Reported Earnings • Mar 13
Full year 2023 earnings released: EPS: CHF10.34 (vs CHF9.53 in FY 2022) Full year 2023 results: EPS: CHF10.34 (up from CHF9.53 in FY 2022). Revenue: CHF1.07b (down 6.1% from FY 2022). Net income: CHF132.1m (up 9.0% from FY 2022). Profit margin: 12% (up from 11% in FY 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has fallen by 1% per year. Buy Or Sell Opportunity • Feb 08
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 19% to CHF335. The fair value is estimated to be CHF274, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 19% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 5.7% per annum. Earnings are also forecast to grow by 13% per annum over the same time period. Tillkännagivande • Feb 06
Tecan Group AG to Report First Half, 2024 Results on Aug 13, 2024 Tecan Group AG announced that they will report first half, 2024 results on Aug 13, 2024 Tillkännagivande • Aug 17
Tecan Group AG Provides Earnings Guidance for the Full Year 2023 Tecan Group AG provided earnings guidance for the full year 2023. For the year, the company continues to forecast sales to increase in the low to mid single-digit percentage range in local currencies. This expectation includes the negative impact of lower COVID-related sales (approximately -4% points for the full year 2023, with the largest share of the impact already recorded in the first half of the year) and the reduced pass-through of material costs (at least -1% point). Underlying sales, which exclude these negative effects, are expected to grow in the high single-digit percentage range in local currencies. Reported Earnings • Aug 17
First half 2023 earnings released: EPS: CHF4.17 (vs CHF5.17 in 1H 2022) First half 2023 results: EPS: CHF4.17 (down from CHF5.17 in 1H 2022). Revenue: CHF541.5m (down 7.3% from 1H 2022). Net income: CHF53.2m (down 19% from 1H 2022). Profit margin: 9.8% (down from 11% in 1H 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in the United Kingdom. Buying Opportunity • Aug 16
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 3.9%. The fair value is estimated to be CHF436, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 19% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 8.1% per annum. Earnings is also forecast to grow by 15% per annum over the same time period. Tillkännagivande • Aug 16
Tecan Group AG to Report Fiscal Year 2023 Results on Mar 12, 2024 Tecan Group AG announced that they will report fiscal year 2023 results on Mar 12, 2024 Tillkännagivande • Aug 15
Tecan Group AG, Annual General Meeting, Apr 18, 2024 Tecan Group AG, Annual General Meeting, Apr 18, 2024. Board Change • May 19
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Christa Kreuzburg was the last independent director to join the board, commencing their role in 2013. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Upcoming Dividend • Apr 13
Upcoming dividend of CHF2.90 per share at 0.7% yield Eligible shareholders must have bought the stock before 20 April 2023. Payment date: 24 April 2023. Payout ratio is a comfortable 30% and this is well supported by cash flows. Trailing yield: 0.7%. Lower than top quartile of British dividend payers (5.9%). In line with average of industry peers (0.7%). Reported Earnings • Mar 15
Full year 2022 earnings released: EPS: CHF9.53 (vs CHF9.95 in FY 2021) Full year 2022 results: EPS: CHF9.53 (down from CHF9.95 in FY 2021). Revenue: CHF1.14b (up 21% from FY 2021). Net income: CHF121.1m (flat on FY 2021). Profit margin: 11% (down from 13% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in the United Kingdom. Tillkännagivande • Dec 08
Tecan Group AG to Report First Half, 2023 Results on Aug 15, 2023 Tecan Group AG announced that they will report first half, 2023 results on Aug 15, 2023 Board Change • Nov 16
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. Director Myra Eskes was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Buying Opportunity • Oct 11
Now 21% undervalued Over the last 90 days, the stock is up 6.6%. The fair value is estimated to be CHF429, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has grown by 19%. Revenue is forecast to grow by 13% in 2 years. Earnings is forecast to grow by 55% in the next 2 years. Board Change • Oct 06
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. Director Myra Eskes was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • Aug 17
Tecan Group AG, Annual General Meeting, Apr 18, 2023 Tecan Group AG, Annual General Meeting, Apr 18, 2023. 
